title: [Age-related macular degeneration].
abstract: The review provides an update on the pathogenesis and new treatment modalities for neovascular age-related macular degeneration (AMD). The impact of polymorphism in particular genes, including complement factor H (CFH), age-related maculopathy susceptibility 2 (ARMS2/LOC387715), and serine peptidase (HTRA1), on AMD development is discussed. Clinical presentations of different forms of exudative AMD, that is classic, occult, or more often mixed choroidal neovascularization, retinal angiomatous proliferation, and choroidal polypoidal vasculopathy, are described. Particular attention is paid to the results of recent clinical trials and safety issues around the therapy.
authors.forename: M V
authors.initials: MV
authors.lastname: Budzinskaia
mesh_terms: D020256:Choroidal Neovascularization / Q000235:genetics*; D017242:Complement Factor H / Q000235:genetics; D019468:Disease Management; D018450:Disease Progression; D020022:Genetic Predisposition to Disease; D000074289:High-Temperature Requirement A Serine Peptidase 1; D006801:Humans; D008268:Macular Degeneration / Q000175:diagnosis / Q000209:etiology / Q000503:physiopathology / Q000628:therapy; D011506:Proteins / Q000235:genetics; D012307:Risk Factors; D012697:Serine Endopeptidases / Q000235:genetics
chemical_list: C514392:ARMS2 protein, human; C493495:CFH protein, human; D011506:Proteins; D017242:Complement Factor H; D000074289:High-Temperature Requirement A Serine Peptidase 1; C474012:HTRA1 protein, human; D012697:Serine Endopeptidases